- This event has passed.
The Art Behind Pharmaceutical and Medical Device Brand Naming (Part 2)
February 3 @ 12:00 pm - 1:00 pm UTC+0
A two-part series on the technical and strategic considerations, and the legal and regulatory challenges of medical product name development Presented by Brand Institute & Drug Safety Institute, a Subsidiary of Brand Institute Scott Piergrossi joined BI in 2003. He oversees the company’s Miami-based operations and corporate communications. In the 16 years preceding his current role, he directed Brand Institute’s naming team, managing all proprietary creative nomenclature projects and developing the creative strategy and methodology used in name development. Mr. Piergrossi received his B.A. in Advertising from Barry University in Miami. Jerry Phillips opened Brand Institute’s regulatory subsidiary, Drug Safety Institute, in 2004 as President & CEO. He was formerly with the FDA for 16 years and acting director of the Division of Medication Errors and Technical Support (DMETS), renamed to Division of Medication Error Prevention & Analysis (DMEPA). Mr. Phillips was responsible for developing the first-generation safety research methodology at the FDA. In 2004, he developed DSI’s infrastructure and methodology to be the global leader in name safety research & regulatory affairs. He then expanded DSI to comply with EMA, Health Canada (HC) and other regulatory authorities. In May 2018, Mr. Phillips transitioned DSI’s responsibilities to Todd Bridges, former FDA DMEPA Director, and took on the responsibilities of Client Relations for the 21 global Brand Institute account teams.
Register here: https://biovalue.webex.com/biovalue/onstage/g.php?MTID=e232ce4fe6f45dd48a1f24a1183d855c1